Glaxo Gets Subpoena in Marketing Probe
GlaxoSmithKline received a subpoena this month from the U.S. attorney’s office in Colorado for an investigation of the marketing and promotion of several of the company’s best-selling products, according to a regulatory filing.
A GlaxoSmithKline spokeswoman said the products cited in the investigation included respiratory drugs Flovent and Advair; Imitrex, used to treat migraines and cluster headaches; Paxil, used to treat depression; anti-viral drug Valtrex; and anti-depressant Wellbutrin.
Shares of GlaxoSmithKline closed at $42.52, down 87 cents, or 2%, on the NYSE.
Sign up for Essential California
The most important California stories and recommendations in your inbox every morning.
You may occasionally receive promotional content from the Los Angeles Times.
